{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Etoricoxib",
  "nciThesaurus": {
    "casRegistry": "202409-33-4",
    "chebiId": "CHEBI:6339",
    "chemicalFormula": "C18H15ClN2O2S",
    "definition": "A synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.",
    "fdaUniiCode": "WRX4NFY03R",
    "identifier": "C52188",
    "preferredName": "Etoricoxib",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1323"
    ],
    "synonyms": [
      "5-Chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) Pyridine",
      "Arcoxia",
      "ETORICOXIB",
      "Etoricoxib",
      "L-791456",
      "MK-0663"
    ]
  }
}